Category Archives: Stem Cell Treatment


2013-2028 Report on Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Player, Region, Type, Application and Sales Channel -…

The research report on Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market offers the effective objectives of the market share, growth aspects, and market segmentation. In addition, the report includes the detailed analysis for significant designing of innovative strategies for service providers. Likewise, this report also provides the collection of information which is gathered for qualitative methodologies as well as survey studied by an experienced analyst. Moreover, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report includes the comprehensive details of the market comprising market trends, growth paths, market opportunities, limitations, challenges, and leading service providers of the respective market for the prediction period.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4155718

In addition, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report delivers the fundamental analysis which is carried out by experienced analysts with a perspective of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry. Furthermore, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report also covers the structures of the industries across the globe. The research report is designed with the help of proficient standardized tools such as SWOT analysis and others. Additionally, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) report offers a brief judgement of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry report offers a broad estimation of the prediction period that will guide the users to take significant decisions over the forecasted chart. This report contain the overall analysis of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market.

Key Players Analysis:

JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecScreenCellSilicon Biosystems

Browse the complete report @ https://www.orbisresearch.com/reports/index/2013-2028-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel

Market split by Type:

CellSearchOthers

Market split by Application:

Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

Market segment by Region/Country including:

North America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Spain etc.)Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)South America Brazil, Argentina, Colombia and Chile etc.)Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

Major Points from Table of Content:

Chapter 1 Market OverviewChapter 2 Market Segment Analysis by PlayerChapter 3 Market Segment Analysis by TypeChapter 4 Market Segment Analysis by ApplicationChapter 5 Market Segment Analysis by Sales ChannelChapter 6 Market Segment Analysis by RegionChapter 7 Profile of Leading PlayersChapter 8 Upstream and Downstream Analysis of Scar DressingChapter 9 Development Trend of (2019-2028)Chapter 10 Appendix

Place a purchase order of this report @ https://www.orbisresearch.com/contact/purchase-single-user/4155718

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 5155

Read more:
2013-2028 Report on Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Player, Region, Type, Application and Sales Channel -...

Hawaii Five-0 To End After 10 Seasons On CBS, Sets Two-Hour Series Finale – Deadline

EXCLUSIVE: CBS Hawaii Five-0 will be coming to an end. The popular action crime drama series will wrap its 10-year, 240-episode run with a two-hour series finale on Friday, April 3.

Primetime-Panic

Your Complete Guide to Pilots and Straight-to-Series orders

Developed by Peter M. Lenkov, Alex Kurtzman and Roberto Orci as a reimagining of Leonard Freemans classic series and shawrun by Lenkov for the shows entire run, Hawaii Five-0 has been a strong profit generator for CBS. In addition to its solid ratings performance, initially on Monday, and as a Friday anchor for the past seven seasons, Hawaii Five-0 has been a big international seller for CBS TV Studios, seen in more than 200 countries. Additionally, it was the last broadcast drama series to score a blockbuster off-network deal, landing $2 million an episode from TNT during its first season on CBS.

Its never easy to say goodbye to a hit franchise that carried on the legacy of the original with such distinction while establishing its own signature style, said Kelly Kahl, President, CBS Entertainment. From episode one, Hawaii Five-0 has been a huge success for us. Thanks to the amazing talents of the producers, writers, cast and crew, it has played a key role for a decade on our schedule and helped establish our powerhouse Friday night. We cannot be prouder of its quality, longevity and are thankful for the passionate fan-devotion it inspired.

Hawaii Five-0 will end its run with its original stars Alex OLoughlin as McGarrett and Scott Caan as Danno. I hear both of their current contracts are up at the end of this season. OLoughlin suffered a serious back injury during the early seasons of the show, and has been dealing with effects from it ever since. There was speculation that he may leave the show two years ago but he stayed on after receiving stem cell treatment. I hear this time around, he felt he could not continue. I hear the network explored continuing Hawaii Five-0 with Caans Danno and a new partner but, ultimately, everyone decided this was the right time to end the series.

This show has been pretty much every waking moment for the last 10 years of my life, said OLoughlin. Everywhere I go on this planet, in every language, I am McGarrett to all these people. What weve done, what weve accomplished, its extraordinary. I cant really put words to express my level of gratitude. Im just glad to have been a part of this, a part of history and Im going to miss it. And to the fans, I dont know how to thank you guys. Thank you for following us the way you have. Im going to miss you. Aloha.

Launching a Hawaii Five-0 reboot had been a top priority for CBS TV Studios for more than a decade. There were multiple unsuccessful attempts with other writers and producers until Lenkov came on board, teaming with Kurtzman and Orci for the pilot. It was the first of a slew of successful reboots Lenkov has delivered for CBS and CBS TV Studios.

Hawaii Five-0 has been such a blessing to me and all of the people who have worked on this incredible show, said Lenkov. I truly learned the meaning of ohana as the viewers embraced us and the people of Hawaii welcomed us with the privilege to film on their shores. I am forever indebted to the creative genius that was Leonard Freeman who gave us such a beautiful story to begin with. And my eternal gratitude to our cast, led by our hero Alex OLoughlin, the writers, the production team, our CBS ohana, and most importantly YOU, the fans, who allowed us to come to work with pride and made our series such a success. Mahalo.

Hawaii Five-0 currently stars OLoughlin, Caan, Ian Anthony Dale, Meaghan Rath, Beulah Koale, Katrina Law, Taylor Wily, Dennis Chun, Kimee Balmilero and Chi McBride.

Like most long-running series, it went through multiple cast transitions. That included the controversial exit of original co-stars Daniel Dae Kim and Grace Park after Season 7. Returning for the two-hour finale are recurring cast members James Marsters (Victor Hesse), William Sadler (John McGarrett) and Mark Dacascos (Wo Fat).

Hawaii Five-0, which consistently wins its time period, has been watched by almost 40 million viewers this season. In addition, the show has ranked in the top 15 or higher of broadcast dramas during its run. Also, Hawaii Five-0, is CBS most social primetime drama, generating 47 million impressions, 3.7 million engagements and 3.8 million video views, season-to-date.

For 10 seasons, Alex, Scott and the rest of the talented Five-0cast have brought fans exciting adventures in a spectacular tropical paradise, said David Stapf, President, CBS Television Studios. We specifically want to thank Peter and the incredibly talented production team for 10 years of consistently outstanding television. The drama has been a great success for the Studio and Network, and as a global franchise for our company. Were pleased to give it a big sendoff and that viewers will have the opportunity to say goodbye to their favorite characters as the final season wraps.

Lenkov executive produces the series with David Wolkove, Matt Wheeler, Kurtzman and Orci.

Link:
Hawaii Five-0 To End After 10 Seasons On CBS, Sets Two-Hour Series Finale - Deadline

Everything you need to know about Myeloma – IOL

By Partnered Content 3h ago

Share this article:

Most of you reading this would have probably never heard of such a disease. My hope is, after taking time to read this, that you will know what myeloma is and have a better understanding of bone marrow cancer in general.

So, lets get started!

Your bone marrow is the factory where all your blood cells are made. This includes red blood cells (they carry the oxygen in your blood), white blood cells (your bodys defence against infections) and platelets (small fragments that prevent and stop bleeding).

The production of these cells by the bone marrow is very well controlled by your body, both in terms of the amount and the type of cells produced. If you have an infection, for instance, your body tells the stem cells in your bone marrow to make more white blood cells to help fight the infection. In such instances, an immature, baby cell gets produced in your bone marrow which then needs to go through various stages of growth and development to become a mature white blood cell. It is then released from the bone marrow into your bloodstream to go and do the job it was destined for, to fight the infection.

This process usually runs quite smoothly, but things can, unfortunately go horribly wrong. Sometimes your body makes a mistake in the production of a white blood cell, almost like a programming error which occurs in the DNA (blueprint) of the cell. It often recognizes its mistake and corrects it, but occasionally this abnormal cell has the ability to hide from your bodys defences, doesnt listen to your bodys commands anymore and can start to increase in number without anything controlling it. This causes a variety of problems and is then called cancer.

Depending on the type of white blood cell and where in its development the programming error occurs, a person can either develop a type of bone marrow cancer (usually leukaemia or myeloma) or lymphoma (glandular cancer), which is also a type of cancer that develops from an abnormal white blood cell.

That brings us to myeloma (also called multiple myeloma or plasma cell myeloma). Myeloma is a type of bone marrow cancer that develops when a programming error occurs in the development of a specific type of white blood cell, called a plasma cell. To understand myeloma better, it is important to understand what role a plasma cell plays under normal circumstances.

They are indeed an integral part of your bodys immune system. Any infection that you may develop gets recognized by your plasma cells. They respond by rapidly producing small proteins called antibodies, which are almost like homing missiles, programmed to go and destroy only that specific virus or bacteria that is making you ill.

After an infection, some of the antibodies remain in your bloodstream and if you are exposed to that exact virus or bacteria again, they are ready to attack immediately, thereby limiting the infection. This is the rationale behind childhood vaccination; to stimulate the production of antibodies which patrol your bloodstream and protect you when you get exposed to infections like measles, polio and many others.

If these plasma cells become cancerous however, they rapidly increase in number, taking over the bone marrow and producing a massive amount of an abnormal antibody which can cause a whole array of problems. This increase in antibody levels in the bloodstream can be measured with a blood test and is also used to monitor the response to treatment.. What are thesymptoms of myeloma?

The abnormal plasma cells in the bone marrow overwhelms the normal bone marrow which most commonly leads to an inability to produce enough red blood cells. This is called anaemia. Symptoms of anaemia are related to the bodys inability to carry sufficient oxygen to your organs and include worsening fatigue, shortness of breath and dizziness.

The abnormal plasma cells also have the ability to weaken your bones. This can either be a generalized loss of bone strength (called osteoporosis), or it can lead to numerous holes being eaten in your bones. This can be seen on an X-Ray or other types of scans. It often results in significant bone pain or even worse, severe fractures with minimal- or even no trauma at all.

Bones are rich in calcium, and if they are being eaten away, their calcium content is released into the bloodstream causing an elevated blood calcium level. This can lead to dehydration, kidney failure and numerous other symptoms.

As mentioned before, the plasma cells in the bone marrow releases a massive amount of abnormal antibodies into the bloodstream. They can clog up your kidneys and cause significant- and often irreversible kidney failure. This can seriously complicate the management of the disease.

These are by far the most common features of myeloma:

Anaemia, bone lesions or fractures, hypercalcaemia and kidney failure.There are numerous other symptoms which can occur, albeit less common.

Is myeloma treatable?

Myeloma is indeed a treatable condition, but there are a couple of important treatment principles to understand.

For most people, myeloma is not a curable disease. It can, however, be carefully managed and the aim of treatment is to provide a good quality of life for as many years as possible. No patients disease is the same and where we sometimes have patients with myeloma living in excess of ten years after being diagnosed, other patients are unfortunately less fortunate and have a form of the disease that is resistant to treatment which can take its toll after only a couple of months.

We perform DNA-tests on the cancer cells and look at various other blood results in an attempt to identify those patients with high-risk disease, who potentially need more intense treatment than others.

The goal of treatment is to destroy as many abnormal plasma cells in the bone marrow as possible. This leads to recovery of the normal bone marrow and minimises the risk of any further complications, giving the body a chance to recover from any complications caused prior to treatment.

For many decades, the backbone of the treatment for myeloma was a combination of two different type of drugs: Chemotherapy and high dosages of cortisone. This is usually quite well tolerated.

The last couple of years, however, have seen an explosion of newer therapies for the treatment of myeloma. This started years ago with the discovery that Thalidomide, was extremely effective for the treatment of myeloma. Soon, more of these so-called novel therapies were developed, leading to a significant increase in the survival of patients who have access to these drugs.

The latest and most impressive of these treatments are certainly the development of monoclonal antibodies and CAR-T cells, both of which are extremely effective even in high risk or resistant myeloma. There is so much excitement about all the newer therapies, but access remains a challenge in theSouth African market.

A strong collaborative effort is required amongst pharmaceutical companies, government and medical schemes, to improve the current access of newer drugs. Nevertheless, some of these drugs have been around for many years and the costs have come down considerably, making it accessible to more people.

The initial treatment of myeloma generally consists of varying combinations of these drugs depending on the patients age, physical condition and of course, the available funding.

We usually use 3 different drugs in combination (a so-called triplet regimen) which has been proven to be very effective. Once the treatment is started, we take blood regularly to monitor the abnormal antibody levels in the blood which, as mentioned earlier, is a surrogate indicator of the number of cancer cells remaining in the bone marrow.

If we dont see a significant downward trend, the disease is likely resistant to that specific treatment combination and treatment should be adjusted accordingly. However, if the antibody levels come down significantly, we are on the right track and can continue with the same treatment until an optimal response is obtained or the development of side-effects forces us to make an adjustment.

After 4-6 months of treatment, the hope is to see no sign of any abnormal antibodies or cancer cells anymore (we call this a remission), or at least a dramatic reduction. We do however know that although we sometimes dont pick up any sign of residual disease, it is merely because the available tests are not sensitive enough. There will always be some cancer cells that remain.

As a general principle, however, the less residual disease, the longer it usually takes before it causes problems again. Because of this, we usually treat younger patients more aggressively in an attempt to obtain a deeper remission. The biggest difference in younger patients is the use of an autologous stem cell transplant as a 2nd phase of treatment to try and obtain or deepen a remission.

We harvest the patients bone marrow stem cells and keep them frozen until needed. We then administer a single high dose chemotherapy which destroys many of the remaining cancer cells, but in the process, it also destroys the normal bone marrow, without which you cannot survive. The patients stem cells are then thawed and given back to them like a blood transfusion.

After about two weeks of close monitoring in the hospital, the stem cells start to function and the patient subsequently has his/her own bone marrow back, hopefully with significantly less myeloma. The age cut-off for such a procedure is arbitrary because it largely depends on the physical condition of the patient. Most people in South Africa, however, use the age of 70 as a cut off, sometimes a bit older if the patient is in exceptional condition for his/her age.

The median age of people diagnosed with myeloma worldwide is about 70 years. The available data, however, suggests that the median age in South Africa is considerably younger, somewhere around the age of 60 years. Due to this, as well as the problems with drug availability in South Africa, we often rely quite heavily on stem cell transplantation as an important part of treatment. If enough stem cells are harvested and cryopreserved, such a transplant can be repeated on numerous occasions to improve disease control.

After a transplant, as well as for those patients who are not candidates for a transplant, a form of low-intensity maintenance therapy is often started as the next phase of treatment in an attempt to keep the disease under control for as long as possible. This duration varies considerably. We hope for a couple of years, but it is unfortunately sometimes just a couple of months before the disease worsens, after which more intense treatment needs to be restarted again and the above cycle repeats itself. The remission duration gives us a good indication regarding the nature and prognosis of the disease.

There is so much more detail about myeloma to share, but the bottom line is this: Although myeloma is not a curable cancer and can lead to devastating complications, there is good treatment available which can help many patients enjoy a good quality of life for many years.

It is important to diagnose myeloma early, so if you have some of the symptoms mentioned earlier, please contact your General Practitioner for further investigation. If any abnormalities are detected, your GP can refer you to aClinical Haematologist, who specialises in bone marrow cancers and are best equipped to treat your myeloma.

We are all very excited about the future of myeloma treatment and hope that the treating physicians, pharmaceutical companies and government can take hands to ensure proper treatment for all the people in South Africa who suffer from this disease.

This article was compiled by Dr. Hannes Koornhof (Chairman of SACHAS)MBChB, FCP (SA), Dip HIV Man (SA), Cert Clin Haematology (SA) PhysSponsored by JANSSEN PHARMACEUTICA(PTY) LTD/(EDMS) BPK. (Reg. No./Regnr. 1980/011122/07); No 2, Medical Road, Halfway House, Midrand, 1685.www.janssen.com.

Medical Info Line: 0860 11 11 17. EM-27036

See original here:
Everything you need to know about Myeloma - IOL

2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market…

The global Stem Cell Alopecia Treatment market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Stem Cell Alopecia Treatment market, offers profound understandings about the Stem Cell Alopecia Treatment market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Stem Cell Alopecia Treatment focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4359779

Manufacturer Detail

By Market Players:

By Application

By TypeAlopecia Areata, Alopecia Totalis, Alopecia Universalis

The Stem Cell Alopecia Treatment market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Stem Cell Alopecia Treatment market. This report on Stem Cell Alopecia Treatment has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Stem Cell Alopecia Treatment research study by HNY Research offers collection of information and analysis for each facet of the Stem Cell Alopecia Treatment market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-uterine-fibroids-treatment-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Alopecia Treatment report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4359779

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read more from the original source:
2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market...

Researchers found a cure for diabetes (in lab mice) – The Next Web

More than 34 million Americans have diabetes, approximately 10% of the population according to the American Diabetes Association. To date, the most common treatment has been to manage the disease with a carefully controlled diet and regular insulin shots, if needed. But a cure may be on the horizon.

A research team led by Jeffrey Millman at Washington University in St. Louis, Missouri found last year that infusing mice with stem cells could offer a better treatment option.

Building on that research, the same team may have found a cure: at least in lab mice.

Diabetics are characterized by their difficulty producing or managing insulin. This requires careful monitoring, a strict diet, exercise, and expensive insulin shots which many diabetics find themselves rationing due to the cost of drugs in the United States. Insulin is normally produced in the pancreas, but those with diabetes dont produce enough of it. To treat diabetes, many diabetics have to monitor their blood sugar levels, and inject insulin directly into the bloodstream as needed. Millmans treatment foregoes these shots and instead uses beta cells to secrete the insulin for you.

The treatment relies on induced pluripotent stem cells (iPS cells). These cells are essentially a blank slate and can be tricked into becoming almost any other type of cell in the body.

In a new study, the team improved on the technique it had developed last year to produce and introduce these cells into the bloodstream. When converting the stem cells into another type of cell, there are always mistakes and random cells enter into the mix along with the insulin-producing ones. These cells are harmless, but they dont pull their weight.

The more off-target cells you get, the less therapeutically relevant cells you have, Millman told New Atlas. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion. It makes curing the disease 25% more difficult.

The new method would rid the sample of those unwanted cells. Millmans team built a process that targeted the cytoskeleton, the structure that gives the cells their shape, and produced not only a higher percentage of effective beta cells, but better functioning ones.

When these new cells were infused into diabetic mice, their blood sugar levels stabilized, leaving them functionally cured of the disease for up to nine months.

Granted, its just an animal trial. The results shouldnt be interpreted as a cure for humans. But its a promising start.

The team plans to continue testing the cells in larger animals, and over longer periods, with their sights set on human clinical trials in the future.

Read next: Smithsonian Institute just released 2.8 million high-quality images for free

See the original post:
Researchers found a cure for diabetes (in lab mice) - The Next Web

United Therapeutics: Buy The Dip – Seeking Alpha

On February 26, United Therapeutics (UTHR) came out with earnings results for the fourth quarter of 2019. The companys revenues of $311.11 million were down YoY by 18.43% and fell short of the consensus by $46.06 million. The companys fourth-quarter non-GAAP EPS (earnings per share) of $1.96 also missed the consensus by $1.43.

Subsequently, the stock is down by 11.97% from $112.86 on February 25 to $100.79 on February 27. I believe that this is an investor overreaction, considering that the dip in revenues and EPS is associated with a one-time event of inventory destocking by a distributor in the fourth quarter. Earlier in 2019, this distributor had placed larger-than-normal orders for the companys products due to an error in its patient utilization data. Hence, the smaller-than-normal order in the fourth quarter was an attempt to normalize inventory levels.

Besides this small glitch, the company boasts of robust fundamentals. Today, we will see why United Therapeutics can prove to be an attractive opportunity in 2020.

United Therapeutics is a biotechnology company focused on developing novel, life-extending therapies in lung disease, oncology, and organ manufacturing indications. The company commercializes therapies including an infused formulation of the prostacyclin analog treprostinil, Remodulin; an inhaled formulation of treprostinil, Tyvaso, and a tablet dosage form of treprostinil, Orenitram; and an oral PDE-5 inhibitor, Adcirca, in PAH (pulmonary arterial hypertension) indication. The company also offers Unituxin, a monoclonal antibody for treating neuroblastoma.

United Therapeutics is now working on developing next-generation technologies for Remodulin, Tyvaso, and Orenitram. The companys R&D pipeline also has investigational novel biologics and NCEs (new chemical entities) targeting various lung, oncology, and organ manufacturing indications.

In July 2002, the company secured FDA approval for Remodulin as a continuous subcutaneous infusion for the treatment of PAH patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. Despite the launch of a generic treprostinil in early 2019, Remodulins sales were only 2% down YoY to $587 million in 2019. In fact, the company reported the highest number of new Remodulin starts in the last ten years.

The YoY decline in Remodulin sales was attributed to a small number of patients switching to the generic drug, as well as to the fact that new patients start on lower dosages of Remodulin and then begin the process of titrating to their effective dose. Since the patient switching trend has all but trickled down, the company now expects U.S. Remodulin patient demand as well as sales to jump up YoY in 2020.

Remodulin demand has been pretty sticky for years. It is a very complex product targeting a very fragile patient population, which places a high premium on years of safety and supply chain reliability.

United Therapeutics is now getting ready to launch the subcutaneous delivery system for Remodulin injections, the RemUnity system, in July 2020. Co-developed by United Therapeutics and Deka Research and Development and cleared by FDA under the FDA 510(K) pathway, the RemUnity system is expected to reduce the risk of bolus dosing due to pump failures and provides wider arrays of notifications, alerts, and alarms than current pumps. Additionally, the RemUnity system will control Remodulin flow rates without the use of a motor. The pump is small and lightweight with a service life of at least three years.

On February 24, the company announced preliminary analysis from Phase 3 INCREASE study evaluating Tyvaso Inhalation Solution in patients suffering from WHO (World Health Organization) Group 3 pulmonary hypertension associated with PH-ILD (interstitial lung disease). The trial met its primary endpoint of demonstrating improvement in 6MWD (six-minute walk distance). In addition to increasing six-minute walk distance by 21 meters versus placebo after 16 weeks of treatment, Tyvaso also demonstrated significant improvements in each of the study's secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Based on the INCREASE results, the company now plans to submit a supplemental new drug application to expand the Tyvasos label in mid-2020.

In June 2019, the company submitted a 505(B)(1) NDA (new drug application) for Trevyent disposable treprostinil pump system. Although the FDA first accepted the application and set PDUFA (prescription drug user fee act) date as April 27, 2020, the agency later included a mid-cycle information request noting several deficiencies in the Trevyent NDA. While the company has already sent its responses to the FDA, based on recent discussions with the FDA, the company expects a delay in the PDUFA date. The company expects this FDA approval in the next 18 months.

United Therapeutics also expects the launch of ISR (Implantable System for Remodulin) codeveloped with Medtronic (MDT) to be delayed to 2021. The delay of the commercial launch is attributable to Medtronic satisfying various conditions to its PMA approval.

United Therapeutics estimates the prevalence of PAH WHO Group 1 in the U.S. to be more than 45,000. The currently approved PAH drugs are for PAH WHO 1 class patients. According to PHA (Pulmonary Hypertension Association), WHO Group 1 refers to pulmonary arterial hypertension (PAH), which is caused when the arteries in the lungs become narrowed, thickened or stiff. The right side of the heart must work harder to push blood through these narrowed arteries. This extra stress can cause the heart to lose its ability to pump enough blood through the lungs to meet the needs of the rest of the body.

However, the prevalence of PAH WHO Group 3 patients in the U.S is even higher, of around more than 130,000 patients. These patients do not have any FDA approved treatment option. Again, according to PHA, WHO Group 3 includes PH due to chronic lung disease and/or hypoxia (low oxygen levels). These lung diseases include obstructive lung disease where the lung airways narrow and make it harder to exhale (e.g. COPD or emphysema); restrictive lung disease in which the lungs have a tough time expanding when one inhales (e.g. interstitial lung disease or pulmonary fibrosis); sleep apnea, and living in an area of high altitude for a long period of time. Arteries in the lungs tighten so that blood can only go to areas of the lungs that are receiving the most air and oxygen. This tightening leads to high blood pressure throughout the lungs.

United Therapeutics is working to increase its total patient base from around 7,500 to 25,000 in the next five years.

Besides Remodulin, Tyvaso and Orenitram also saw the highest patient demand in 2019 as compared to the last four years.

Then again, United Therapeutics expects RemUnity, Trevyent, ISR, and Smart Pump technology to have a very favorable impact on future patient demand and sales of Remodulin. The company also expects label expansion of Tyvaso based on the INCREASE study to increase the addressable U.S. population by more than 30,000 patients. This will also position the Tyvaso as a treatment option for a section of the PAH WHO Group 3 patients, those with interstitial lung disease. The company is studying Tyvaso in COPD (chronic obstructive pulmonary disorder) patients in the Phase 3 PERFECT study. Finally, the expanded label of Orenitram based on the FREEDOM-EV trial highlighting superior morbidity and mortality outcomes is also helping to attract new PAH patients.

United Therapeutics is now studying Tyvaso in PH WHO Group 3 patients, PH COPD patients, in Phase 3 trial PERFECT. The company seems to have high hopes for the success of the trial after robust results from the INCREASE study since inhaled therapies can avoid the VQ (Ventilation Perfusion Mismatch), as is seen in system therapies targeting lung diseases. The PERFECT trial is currently 20% enrolled.

Besides studying already approved products for additional indications, the company also has a slew of investigational NCEs and biologics in its pipeline.

United Therapeutics expects investigational Phase 3 asset, ralinepag, to transform the care of WHO Group I PH patients. The company is also studying a gene therapy study in the Phase 3 trial, SAPPHIRE, to make PH treatment more convenient with just a once quarterly infusion of genetically engineered autologous stem cells from the patient. The company expects enrollment to be completed in 2021, and product launch by 2025. Finally, the company is attempting its hand at the much challenging and lucrative organ manufacturing segment.

The biggest risk weighing down on United Therapeutics valuation is the potential impact of generic erosion of Remodulin. The company depends extensively on its topline on the treprostinil franchise, exposing it to significant business concentration risk.

The company is exposed to R&D failure risk and subsequent contraction in probable growth drivers. The most recent example of such a failed trial is the phase 2/3 DISTINCT study evaluating Unituxin in Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory SCLC (small cell lung cancer). On February 3, 2020, the company announced that this trial did not meet its primary endpoint of extending OS (overall survival).

According to finviz, the 12-month consensus target price of the company is $122.22. On February 27, Cowen analyst Chris Shibutani upgraded United Therapeutics from Market Perform to Outperform and raised the price target from $119 to $145. On February 25, Wedbush analyst Liana Moussatos raised her price target from $237 to $243 and reiterated Outperform rating for the stock. On February 13, Credit Suisse analyst Martin Auster reiterated the Outperform rating and raised his price target from $113 to $121. On January 31, JPMorgan analyst Jessica Fye revised upwards United Therapeutics rating from Neutral to Overweight and price target from $116 to $120. On December 27, Oppenheimer analyst Hartaj Singh reiterated the Outperform rating and $155 target price.

We see that the overall analyst sentiment and target price have consistently improved for the company since March 2019.

Based on the companys robust product portfolio, strong pipeline, and multiple upcoming catalysts, I believe that $145 is a fair estimate of the true value of the company. I believe that retail investors with above-average risk appetite should consider buying the company on the latest dip in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
United Therapeutics: Buy The Dip - Seeking Alpha

Stem Cell Treatment

Amyotrophic Lateral Sclerosis (ALS) is a form of motor neuron disease that leads to the gradual degeneration of voluntary muscle movement. In the early stages of ALS, many of those affected have to deal with weakening of the muscles, difficulties with speaking and swallowing, and in many cases severe pain as a result. In the later stages, most patients cannot walk, talk, swallow or breathe unassisted. The figures for ALS - which is also known as Lou Gehrigs disease - are quite shocking. Read MoreAutism Spectrum Disorder (ASD) is a developmental disability, which usually lasts for the duration of a persons life. For a person with autism, the world around them is experienced in a different way, and they may find it more difficult to deal with interactions with others. This can be in the form of struggling with normal communication, but it can also mean that they find it hard to tell how other people are thinking and feeling. Read MoreOriginating in the brain, Parkinsons Disease occurs when dopamine-producing cells within the brain stop working. As a result of dopamine no longer being produced, patients with Parkinsons Disease begin experiencing a range of symptoms. Motor symptoms, such as muscle rigidity, tremors, and slowing of movement, are among the most common symptoms of Parkinsons, but patients may also experience a wide range of other symptoms as well. Common non-motor symptoms caused by Parkinsons include pain, depression, insomnia, memory problems, anxiety, and fatigue, as well as bladder and/or bowel problems. Read More

The rest is here:
Stem Cell Treatment

Stem Cell Therapy | ANOVA IRM

What is Regenerative Medicine?

Regenerative Medicine is a new field of medicine with one goal in mind: to heal and restore normal function of damaged tissues and organs. Just like the human body itself, regenerative medicine utilizes stem cells to replace damaged cells and tissues. Stem Cells are, therefore, considered to be one of the most powerful tools in treating diseases. They go beyond conventional methods to repair and regenerate disease-related damage, by returning tissues and organs to a healthier state.

Stem cells exist in many different types as they have been identified in various tissues and organs. Each type of stem cell is classified by: their origin in the body, and their potential (potency) to differentiate (transform) into other cell types. This potential varies among stem cell types.

Some stem cells are capable of differentiating themselves into any cell type of body (pluripotent). Others, on the other hand, are able to transform into many cell types (multipotent), while some are only able to differentiate themselves into few (oligopotent) or one cell type (unipotent).

Having this in mind, it is important to note that not all stem cell types are suitable for treating patients. For example, the use of Embryonic Stem Cells (ESCs) for treating patients is restricted due to ethical issues, and their potential to grow into tumors.

One of the safest and most effective forms of stem cell treatments, which we employ at ANOVA, make use of autologous stem cells, i.e. stem cells derived from the patient themselves. By using autologous stem cells for the treatment of patients, there is very minimal to no risk of tumor formation, the transmission of infectious diseases or adverse immune reactions.

Bone Marrow Concentrate (BMC) and Mesenchymal Stem Cells (MSCs) are the most abundant form of autologous adult stem cells that are well suited for clinical use. They are relatively easily harvested from the bone marrow (BMCs) or from the subcutaneous ("under the skin") fat (MSCs).

Currently, most therapies at ANOVA are based on cell-free secretion of MSCs. We are also offering combination therapies with Platelet Rich Plasma (PRP), a medium that is rich in growth factors and other cytokines (molecules from the immune system) that stimulates healing, as well as BMC in the near future. Both can additionally be supplemented with our stem cell treatments as they seamlessly synergize together.

ANOVA offers individualized stem cell therapies that are best suited for the particular condition of the patient, and for the patient only. The application of these therapies depends entirely on the patients medical condition.

Overview

Numerous types of stem cell therapies are available at ANOVA. Stem cell research brought insights that allowed for technological advancements in therapies and expanding the knowledge of the underlying mechanisms of stem cells. This has allowed for more effective therapies to be developed.

BMC

Bone Marrow Concentrate (BMC) is one of the most commonly applied source of stem cells. Despite the fact that the actual number of stem cells in BMC is biologically limited, several other (regenerative) factors in BMC have been shown to deliver promising results in the treatment of numerous diseases.

Stem Cell Secretome

Stem Cell Therapies 2.0: The ANOVA Stem Cell Secretome Therapy is the next generation of stem cell-based therapies. It was designed to harness and mass produce the healing essences of stem cells (paracrine and regenerative factors, extracellular vesicles, exosomes) in a uniquely designed laboratory process.

MSCs

Fat (adipose) derived Mesenchymal Stem Cells (MSC | adMSCs) are a commonly used source of stem cells, because of their availability and robustness. They communicate to other cells with a broad spectrum of secreted paracrine and regenerative factors. They are our favorite source of stem cells for the production of the secretome.

Platelet Rich Plasma (PRP)

Platelet Rich Plasma (PRP) is a blood-derived, cellular product with concentrated supply of regenerative growth factors and cytokines. Its efficacy has been proven in some orthopedic conditions. When used in combination with our stem cell therapies, its efficacy is synergistically enhanced.

Stem Cells, as explained previously, have the power to differentiate into any cell type, all the way from: bone cells to brain cells, heart cells, nerve cells, kidney cells, etc. This is what defines Stem Cells. However, the potency to differentiate into any body cell type is not what defines their healing powers, as not all stem cell types are able to transform into any cell type. Only a selected few, such as Bone Marrow (BMC) and Mesenchymal Stem Cells (MSCs), have been identified to differentiate into most cells type and have been successfully used in medicine to treat diseases. They have been shown to hold several major therapeutic effects, such as:

After initial damage to tissues or organs, such as mechanical forces in trauma or the lack of blood supply in strokes and heart attacks, further damage is caused by immune processes and inflammation. Subcritically injured cells, which are usually found in the vicinity of the damaged tissue or organ, primarily commit suicide instead of repairing themselves. This process further increases the damaged tissue volume. To repair this damage, which is (potentially) possible in most organs by the specific stem cells residing in them, is very slow or does not happen at all without external stimulation. In such cases, stem cells therapies have been demonstrated to be extremely effective in stimulating repair and limiting further damage.

Early stem cell research indicated that stem cells heal by replacing damaged cells in injured organs. Now, it has become evident that the major effects of tissue repair are not entirely based on direct stem cell implantation, but rather by the secretion of soluble (paracrine) factors from the stem cells themselves.

This discovery has prompted the Anova scientists to explore a completely new therapeutical approach in regenerative medicine, which has ultimately lead to the development of our novel, safe, cell-free treatment: The ANOVA's Stem Cell Secretome Therapy.

ANOVA's Stem Cell therapy method utilizes autologous stem cells, i.e. cells that are derived from the patient itself, to mass produce the secretory factors (that retain the regenerative powers of stem cells), At Anova, a minimally invasive mini-liposuction procedure is performed, which allows for the isolation of stem cells from the subcutaneous fat (adipose tissue) of the patient.

This method does not rely on direct stem cell transplantation to treat numerous diseases and support anti-aging. Latest scientific research has shown that stem cell-free therapies, such as at Anova's, offer the same efficacy as traditional stem cell transplantation therapies, with higher safety and minimized risk for the patient.

Read more:
Stem Cell Therapy | ANOVA IRM

Stem Cell Therapy for COPD: What You Need to Know | COPD.net

When you have a chronic, incurable disease, its natural to be interested in research and new therapies that might offer hope and a solution that current treatments do not. Stem cell therapy is one of the most talked about and advertised potential new COPD treatments today. Its hard to do any search for COPD on the Internet without running into an ad or claim about stem cell therapy for COPD. In fact, one of the most highly regarded COPD blogs push stem cell treatment in almost every article they publish.

But is this a valid treatment? Or it some kind of scam?

Stem cells are a type of cell in the body that can regenerate on their own. During normal cell division,each new cell can choose either to remain a stem cell or become a different type of cell with a more specialized function. For example, stem cells might become muscle cells, red blood cells or brain cells. In some cases, they have proven useful as a sort of internal repair system.1

So, in other words, stem cells differ from other types of cells in two ways: 1

In the gut and bone marrow, stem cells regularly divide and repair or replenish the body tissues on their own. On the other hand, in other types of body organs, such as the heart and pancreas, stem cells will only behave like that when special conditions exist.

Stem cells can be obtained from both embryos (notably, mouse embryos) and adult tissues. Stem cells in embryos are what eventually morph into the entire organism. In adults,stem cells become replacements for cells that have been lost through normal wear and tear, injury, or disease. 1

Because of their regenerative abilities, stem cells do seem to offer some hope for treating certain illnesses. However, there is still much research to be done to prove the safety and effectiveness of stem cell therapy. Most research to date has been done in laboratories with mice, not with humans in the real world.

Also, while embryonic stem cells are able to replicate and form different types of specialized cells, the same may not be true for adult stem cells. Instead adult cells tend to generate the same types of cells as in the organ where they reside.1 Some scientists believe stem cells can be reprogrammed, given the right conditions. Whether or not this is true is a big debate in the scientific community.

While stem cells have been identified in many other parts of the body, experts did not believe they existed in lung tissue until the last decade or so. With this discovery, there was a surge of interest in using stem cell therapy for COPD.2

Certain cells in the smallest parts of your airways, the alveoli, can be destroyed by tobacco smoking or regular exposure to other harmful substances. This leads to difficulties in gas exchange (oxygen and carbon dioxide), resulting in the typical symptoms of COPD.3 Research done in the lab on animal models has shown promise in:3

However, to date, human clinical trials have failed to show any real benefit when stem cell therapy is used to treat COPD.3 Some experts theorize that result might be better when stem cell therapy is used earlier on in the development of COPD. However, the alternate take on this is that more traditional forms of therapy are also more effective when begun early. So there may be no real advantage to stem cell treatment. Or, could there be? We just dont know yet.

TheInternational Society for Stem Cell Research published an extensive article on things to be aware of when it comes to stem cell therapy.4 I highly encourage you to read it before pursuing stem cell therapy for COPD. They caution:

Many clinics offering stem cell treatments make claims that are not supported by a current understanding of science.

Here is a synopsis of their advice:

Also, most stem cell therapy clinics are extremely expensive and are not covered by insurance. And they do not offer a guarantee that theyll even work, especially for COPD.

Stem cell research is extremely promising. There have already been successes in treating blood-related diseases with stem cells derived from the blood.5 On the other hand, the results have been quite mixed when using stem cell therapy for other diseases, especially COPD. But research is progressing and more clinical trials are being developed each year. So perhaps one day soon, we will see a viable stem cell therapy for COPD. But that day has not yet arrived, no matter what youve heard.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The COPD.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

See the original post:
Stem Cell Therapy for COPD: What You Need to Know | COPD.net

Stem Cell Therapy for Erectile Dysfunction | Stem Cell …

*Note: For the investigational use of Adipose-Derived Stem Cells (ADSCs) for clinical research and deployment.

Erectile Dysfunction (ED) can have an emotional impact on men, affecting both self-confidence and personal relationships. For many years, treatment for ED was palliative in nature and relied on the use of medication in a timely manner. Although popular medications can be successful in enabling an erection in approximately 75% of patients, the inability to be truly spontaneous in intimacy and possible side effects often diminished their true effectiveness. In addition, medications can begin to lose effectiveness or stop working completely when used continuously.

Recent scientific studies have shed light on both the underlying causes of ED and new treatment options that address them, instead of treating only the symptoms. There are exciting new treatment options for men suffering from erectile dysfunction that can provide natural and lasting results without medication, including stem cell therapy. A pioneer in the use of stem cells for regenerative medicine, Dr. Todd Malan offers treatment for ED that uses the bodys own resources to repair damaged tissue and restore your ability to experience sexual satisfaction with a spontaneous erection.

Using stem cells, Dr. Todd Malan is able to help men achieve stronger and longer-lasting erections without the use of medications or external support devices. Stem cells actually repair damaged blood vessels for improved blood flow, making this a truly regenerative treatment.

In the past, erectile dysfunction was believed to be a psychological condition. We now know that there are a number of factors that can contribute to ED. It is a very common condition, affecting as many as 30 million men in the United States. Impotence can affect any man at any age, however, it is more common in older men. The incidence of erectile dysfunction also increases with age. Major risk factors include:

One of the most common reasons for erectile dysfunction is damaged blood vessels and reduced blood flow to the penis, which can be caused by any of the factors above. The ability to achieve and maintain an erection is dependent on the capability of the veins in the penis to respond to certain stimulation. Blood vessels must also be able to maintain dilation for the maintenance of an erection. With age, those veins begin to have micro-damage, which is normal with all blood vessels in every area of the body.

Dr. Malan is able to repair that damage with stem cell therapy so that the blood vessels are able to better respond to a stimulus due to sufficient blood flow and produce a stable, more prominent erection.

The Era of Regenerative Medicine: New Hope for Treating EDIt is estimated that as many as 30 million men in the United States are affected by erectile dysfunction. Past treatments focused on the management of symptoms. Stem cells are being widely used by medical doctors to regenerate damaged tissues and blood vessels. In sports medicine, stems cells are highly effective in repairing musculoskeletal injuries.

Applying this knowledge to the treatment of erectile dysfunction, Dr. Malan and other leading physicians are using stem cells to regenerate damaged blood vessels in the penis. These therapies help men achieve longer-lasting, much larger erections than they would normally be able to achieve. Because stem cells have the ability to replicate themselves, they can actually heal the damaged vessels.

There are many different types of stem cells. For the treatment of erectile dysfunction, three types of adult stem cells are commonly used:

Dr. Malan is a pioneer in the use of ADSC. He has developed a technique that involves the use of advanced liposuction to harvest fat cells and a sophisticated purification process to produce a stem cell-rich gel that is then injected into the blood vessels in the penis.

Why Fat Stem Cells?Harvesting adipose-derived stem cells (ADSCs) is much easier and less invasive than harvesting either bone marrow or muscle-derived stem cells. Fat is abundant in the body and is obtained using minimally invasive liposuction. ADSCs have a significantly higher concentration of mesenchymal stem cells, which have the ability to self-renew, clone, and differentiate into multiple tissues.

This procedure is also referred to as autologous stem cell therapy, which means the donor and the recipient are the same people. Because of the high volume of stem cells found in fat tissue, there is no need to culture the cells or wait for them to grow. They can be harvested, concentrated into a stem cell-rich mixture and re-injected into the treatment area on the same day of the procedure.

Throughout the United States, it is popular among doctors to use liquid-based stem cells. Dr. Malan uses the latest technique, developed in Europe, to use a gel or paste stem cell mixtures, which produce far better results.

You dont need to leave the United States to get expert treatment.The Innovative Cosmetic Surgery Center is a leader in stem cell therapies. Dr. Malan trains physicians from around the world in this and other procedures. Our treatments are performed according to FDA standards in our Scottsdale clinic. Your safety and comfort are our foremost concern.

Arizona is the ideal location for a medical vacation. We offer free virtual consultations to discuss your concerns and treatment options. Dr. Malan hosts men from all over the United States for the treatment of erectile dysfunction. Explore your options. Call us at (480) 998-7999 or request an appointment online.

If youve been suffering from erectile dysfunction, now is the time to do something about it. Stem cell therapy is highly effective, minimally invasive and completely safe for the treatment of ED. We routinely host men from all over the United States and will help coordinate the details of your travel if you are out of state.

Call us today for a consultation (480) 998-7999 or request an appointment online.

More here:
Stem Cell Therapy for Erectile Dysfunction | Stem Cell ...